Article
Microbiology
Devin Sindeldecker, Shaurya Prakash, Paul Stoodley
Summary: This study analyzed the zone of killing (ZOK) in Pseudomonas aeruginosa biofilms using both in vitro and in silico methods. The findings revealed that achieving a specific antibiotic concentration versus time constraint (AUC) could completely eradicate bacteria in the biofilms. This suggests that appropriate antibiotic concentrations and treatment duration may be effective against antibiotic-resistant and -tolerant biofilm infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Chelsey M. VanDrisse, Rosalie Lipsh-Sokolik, Olga Khersonsky, Sarel J. Fleishman, Dianne K. Newman
Summary: This study demonstrates that by engineering the structure of PodA protein and combining it with tobramycin, the killing effect on P. aeruginosa can be enhanced, especially on biofilms that are resistant to conventional antibiotic treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Microbiology
Xuerui Bao, Ellen Goeteyn, Aurelie Crabbe, Tom Coenye
Summary: D,L-malate enhances ciprofloxacin activity against P. aeruginosa, improving antibiotic therapy in infection environments. The choice of model system influences the outcome of the experiment, emphasizing the importance of using models that closely mimic the in vivo environment. This study confirms the potential of D,L-malate to enhance ciprofloxacin activity against P. aeruginosa-associated infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Pharmacology & Pharmacy
Nuoyan Wang, Xuemin Chen, Jing Luo, Fei Deng, Fuguo Shi, Qin Wu, Yasi Huang, Qin Ouyang, Rongxin Qin, Hong Zhou
Summary: This study investigated the antibacterial sensitization effect of DHA27 combined with tobramycin in tobramycin-resistant Pseudomonas aeruginosa. The combination showed significant antibacterial effects on many resistant strains and reduced bacterial load in the spleen and lungs in a mouse model. The study also revealed that the effect was related to the inhibition of mRNA expression of aminoglycoside-modifying enzymes.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Wanlin Li, Ximian Xiao, Yuchen Qi, Xiuhui Lin, Huiqun Hu, Minqi Shi, Weinan Jiang, Longqiang Liu, Kang Chen, Kai Wang, Runhui Liu, Min Zhou
Summary: In this study, a host-defense-peptide-mimicking beta-peptide polymer was developed as a potential treatment for bacterial infection diseases. The polymer showed resistance to proteolysis, enhanced antimicrobial activity, and low cost for preparation. It also demonstrated quorum sensing interference and bactericidal effects, leading to effective biofilm eradication and virulence reduction. Additionally, the beta-peptide polymer showed therapeutic effects in Pseudomonas aeruginosa pneumonia and Escherichia coli pyogenic liver abscess.
Article
Biochemistry & Molecular Biology
Uthaibhorn Singkham-In, Pornpimol Phuengmaung, Jiradej Makjaroen, Wilasinee Saisorn, Thansita Bhunyakarnjanarat, Tanittha Chatsuwan, Chintana Chirathaworn, Wiwat Chancharoenthana, Asada Leelahavanichkul
Summary: In this study, it was found that Pseudomonas aeruginosa adapted to Chlorhexidine exhibited differences in morphology, metabolism, and biofilm characteristics compared to the parent strain. Moreover, the Chlorhexidine-adapted strain developed resistance to Chlorhexidine and colistin through the overexpression of psl genes. Additionally, it was observed that Chlorhexidine-induced activation of bacteria resulted in lower inflammatory reactions compared to the parent strain.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Xuerui Bao, Mona Bove, Tom Coenye
Summary: The high tolerance of Pseudomonas aeruginosa biofilms in respiratory tract infections in cystic fibrosis contributes to the failure of antibiotic therapy. This study identified carbon sources that could enhance the inhibiting and/or eradicating activity of tobramycin, ciprofloxacin, and ceftazidime against P. aeruginosa PAO1 biofilms. The mechanisms underlying the enhanced biofilm eradicating activity were strain-dependent.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Ecology
Thomas James O'Brien, Wendy Figueroa, Martin Welch
Summary: The presence of diverse polymicrobial communities in the airways of individuals with cystic fibrosis can hinder the effectiveness of antibiotic treatment. A study showed that growth in a polymicrobial environment protects the target microorganism from the effects of specific antimicrobial agents. This decreased efficacy is found to have both physiological and genetic components.
Article
Microbiology
Fernanda Jimenez Otero, Dianne K. Newman, Leonard M. Tender
Summary: Biofilms provide a protective environment but also present challenges to the cells living within them. Pseudomonas aeruginosa overcomes oxygen limitation by secreting redox active phenazines, which act as electron shuttles. Blocking the re-oxidation of one of these electron shuttles, pyocyanin, decreases cell survival within biofilms and enhances the effect of gentamicin in killing cells. The study highlights the importance of redox cycling of electron shuttles in P. aeruginosa biofilms.
Article
Microbiology
Amal H. Yahya, Sophie R. Harston, William L. Colton, Matthew T. Cabeen
Summary: Pseudomonas aeruginosa is a common pathogen that infects hospitalized patients and individuals with cystic fibrosis. This species is known for forming biofilms, which provide extra protection to the cells and make infections difficult to treat. The deletion of the gene PA14_16550 reduces biofilm formation, and further investigations have identified other genes that regulate biofilm matrix production.
MICROBIOLOGY SPECTRUM
(2023)
Article
Pharmacology & Pharmacy
Reham Aljalamdeh, Robert Price, Matthew D. Jones, Albert Bolhuis
Summary: Pseudomonas aeruginosa is a common bacteria causing chronic respiratory infections in cystic fibrosis patients. Biofilms formed by this bacterium are highly resistant to antibiotics. The size of tobramycin particles in dry powder inhalers can influence their efficacy against P. aeruginosa biofilms, with smaller particles showing better results within a 3-hour treatment period.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Article
Microbiology
Negar Mozaheb, Patrick van der Smissen, Tomas Opsomer, Eric Mignolet, Romano Terrasi, Adrien Paquot, Yvan Larondelle, Wim Dehaen, Giulio G. Muccioli, Marie-Paule Mingeot-Leclercq
Summary: Membrane rigidification is an important survival strategy in Pseudomonas aeruginosa exposed to stress. This study highlights the role of bacterial membrane vesicles (MVs) in altering membrane fluidity. The results show that biofilm P. aeruginosa has a less fluid membrane compared to planktonic bacteria, and the ability to decrease membrane fluidity can be transferred via MVs. Understanding the conditions leading to membrane rigidification could contribute to developing therapeutic approaches against this resistant pathogen.
Review
Cardiac & Cardiovascular Systems
J. Stuart Elborn, Francesco Blasi, Charles S. Haworth, Manfred Ballmann, Harm A. W. M. Tiddens, Marlene Murris-Espin, James D. Chalmers, Andre M. Cantin
Summary: Inhaled tobramycin therapy has shown effectiveness in reducing P. aeruginosa microbial density in sputum of bronchiectasis patients, leading to potential clinical benefits such as reduced hospitalizations, exacerbations, and symptoms. Definitive phase 3 trials are needed to determine the clinical efficacy and long-term safety of inhaled tobramycin in bronchiectasis patients with chronic P. aeruginosa infection.
RESPIRATORY MEDICINE
(2022)
Review
Microbiology
Gina A. Suh, Thomas P. Lodise, Pranita D. Tamma, Jane M. Knisely, Jose Alexander, Saima Aslam, Karen D. Barton, Erica Bizzell, Katherine M. C. Totten, Joseph L. Campbell, Benjamin K. Chan, Scott A. Cunningham, Katherine E. Goodman, Kerryl E. Greenwood-Quaintance, Anthony D. Harris, Shayla Hesse, Anthony Maresso, Veronique Nussenblatt, David Pride, Michael J. Rybak, Zoe Sund, David van Duin, Daria Van Tyne, Robin Patel
Summary: Due to increasing antimicrobial resistance and medical device-related infections, phage therapy has gained renewed interest as an alternative or adjunct to conventional antimicrobials. However, there are significant knowledge gaps in clinical application and laboratory testing of phage therapy, leading to heterogeneity in approach and lack of consensus.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Microbiology
Kimberly K. Kajihara, Homer Pantua, Hilda Hernandez-Barry, Meredith Hazen, Kiran Deshmukh, Nancy Chiang, Rachana Ohri, Erick R. Castellanos, Lynn Martin, Marissa L. Matsumoto, Jian Payandeh, Kelly M. Storek, Kellen Schneider, Peter A. Smith, Michael F. T. Koehler, Siao Ping Tsai, Richard Vandlen, Kelly M. Loyet, Gerald Nakamura, Thomas Pillow, Dhaya Seshasayee, Sharookh B. Kapadia, Wouter L. W. Hazenbos
Summary: This study demonstrates that an anti-P. aeruginosa AAC can locally concentrate antibiotic and kill P. aeruginosa inside phagocytes, providing additional therapeutic options for antibiotics that are moderately active or have an unfavorable pharmacokinetics or toxicity profile. This approach may provide new therapeutic options for antibiotics that are dose limited.